Format

Send to

Choose Destination
Kidney Int. 2017 Jul;92(1):26-36. doi: 10.1016/j.kint.2017.04.006.

Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.

Author information

1
Klinikum Coburg, Coburg, Germany. Electronic address: markus.ketteler@klinikum-coburg.de.
2
Denver Nephrology, Denver, Colorado, USA.
3
University Hospitals Leuven, Leuven, Belgium.
4
Tokai University School of Medicine, Isehara, Japan.
5
Hennepin County Medical Center, Minneapolis, Minnesota, USA.
6
Eagle, Idaho, USA.
7
Indiana University School of Medicine, Indianapolis, Indiana, USA; Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, USA.
8
Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.
9
University of Calgary, Calgary, Canada.
10
The Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
11
VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
12
Stanford University School of Medicine, Stanford, California, USA. Electronic address: leonard5@stanford.edu.

Abstract

The KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD represents a selective update of the prior CKD-MBD Guideline published in 2009. This update, along with the 2009 publication, is intended to assist the practitioner caring for adults and children with chronic kidney disease (CKD), those on chronic dialysis therapy, or individuals with a kidney transplant. This review highlights key aspects of the 2017 CKD-MBD Guideline Update, with an emphasis on the rationale for the changes made to the original guideline document. Topic areas encompassing updated recommendations include diagnosis of bone abnormalities in CKD-mineral and bone disorder (MBD), treatment of CKD-MBD by targeting phosphate lowering and calcium maintenance, treatment of abnormalities in parathyroid hormone in CKD-MBD, treatment of bone abnormalities by antiresorptives and other osteoporosis therapies, and evaluation and treatment of kidney transplant bone disease.

KEYWORDS:

KDIGO CKD-MBD Guideline; bone mineral density; calcium; dialysis; hyperparathyroidism; hyperphosphatemia; kidney transplantation

PMID:
28646995
DOI:
10.1016/j.kint.2017.04.006
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center